Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Apr;67(4):798–800. doi: 10.1038/bjc.1993.145

Effect of alternating combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide for small cell lung cancer on hematopoietic progenitors in the peripheral blood.

E Shimizu 1, A Yamamoto 1, Y Takahashi 1, K Maniwa 1, S Yoshida 1, J Mukai 1, Y Takaue 1, T Ogura 1
PMCID: PMC1968335  PMID: 8385979

Abstract

The effects of a combination chemotherapy (CAV-PVP) consisting of cyclophosphamide, doxorubicin, hydrochloride (dox) and vincristine (CAV) alternating with cisplatin and etoposide (PVP) on peripheral blood hematopoietic progenitor cells (PBHPs) were studied in five patients with small cell lung cancer (SCLC). The kinetics of the CFU-GM levels were different during the CAV and PVP phases. None of the five patients displayed a rebound increase in the level of peripheral blood CFU-GM during the CAV phase. In contrast, all five patients displayed a rebound increase in peripheral blood CFU-GM levels during the PVP phase of the alternative combination chemotherapy (3-5 weeks after the initiation of PVP regimen). These findings indicate the optimal timing for leukapheresis to obtain PBHPs in SCLC patients which have been treated with an alternating combination chemotherapy consisting of CAV-PVP.

Full text

PDF
798

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams R. A., Johnston-Early A., Kramer C., Minna J. D., Cohen M. H., Deisseroth A. B. Amplification of circulating granulocyte-monocyte stem cell numbers following chemotherapy in patients with extensive small cell carcinoma of the lung. Cancer Res. 1981 Jan;41(1):35–41. [PubMed] [Google Scholar]
  2. Caracciolo D., Clark S., Rovera G. Differential activity of recombinant colony-stimulating factors in supporting proliferation of human peripheral blood and bone marrow myeloid progenitors in culture. Br J Haematol. 1989 Jul;72(3):306–311. doi: 10.1111/j.1365-2141.1989.tb07709.x. [DOI] [PubMed] [Google Scholar]
  3. Evans W. K., Feld R., Murray N., Willan A., Coy P., Osoba D., Shepherd F. A., Clark D. A., Levitt M., MacDonald A. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med. 1987 Oct;107(4):451–458. doi: 10.7326/0003-4819-107-4-451. [DOI] [PubMed] [Google Scholar]
  4. Fukuoka M., Furuse K., Saijo N., Nishiwaki Y., Ikegami H., Tamura T., Shimoyama M., Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991 Jun 19;83(12):855–861. doi: 10.1093/jnci/83.12.855. [DOI] [PubMed] [Google Scholar]
  5. Gale R. P., Henon P., Juttner C. Blood stem cell transplants come of age. Bone Marrow Transplant. 1992 Mar;9(3):151–155. [PubMed] [Google Scholar]
  6. Goldie J. H., Coldman A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727–1733. [PubMed] [Google Scholar]
  7. Goldie J. H., Coldman A. J., Gudauskas G. A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982 Mar;66(3):439–449. [PubMed] [Google Scholar]
  8. Henon P. R., Butturini A., Gale R. P. Blood-derived haematopoietic cell transplants: blood to blood? Lancet. 1991 Apr 20;337(8747):961–963. doi: 10.1016/0140-6736(91)91583-g. [DOI] [PubMed] [Google Scholar]
  9. Kessinger A., Armitage J. O. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood. 1991 Jan 15;77(2):211–213. [PubMed] [Google Scholar]
  10. Kotasek D., Shepherd K. M., Sage R. E., Dale B. M., Norman J. E., Charles P., Gregg A., Pillow A., Bolton A. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant. 1992 Jan;9(1):11–17. [PubMed] [Google Scholar]
  11. Körbling M., Juttner C., Henon P., Kessinger A. Autologous blood stem cell versus bone marrow transplantation. Bone Marrow Transplant. 1992;10 (Suppl 1):144–148. [PubMed] [Google Scholar]
  12. Menichella G., Pierelli L., Foddai M. L., Paoloni A., Vittori M., Serafini R., Benedetti Panici P., Scambia G., Baiocchi G., Greggi S. Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. Br J Haematol. 1991 Nov;79(3):444–450. doi: 10.1111/j.1365-2141.1991.tb08053.x. [DOI] [PubMed] [Google Scholar]
  13. Mukai J., Shimizu E., Takaue Y., Ogura T. Effect of chemotherapy on colony-forming unit-granulocyte macrophage from bone marrow and peripheral blood in patients with lung cancer. Oncology. 1992;49(1):45–48. doi: 10.1159/000227009. [DOI] [PubMed] [Google Scholar]
  14. Shimizu E., Mukai J. N., Takaue Y., Ogura T. Circulating hematopoietic progenitors in patients with primary lung cancer. Jpn J Cancer Res. 1990 Dec;81(12):1293–1299. doi: 10.1111/j.1349-7006.1990.tb02693.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Siena S., Bregni M., Brando B., Belli N., Ravagnani F., Gandola L., Stern A. C., Lansdorp P. M., Bonadonna G., Gianni A. M. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood. 1991 Jan 15;77(2):400–409. [PubMed] [Google Scholar]
  16. Takaue Y., Kawano Y., Reading C. L., Watanabe T., Abe T., Ninomiya T., Shimizu E., Ogura T., Kuroda Y., Yokobayashi A. Effects of recombinant human G-CSF, GM-CSF, IL-3, and IL-1 alpha on the growth of purified human peripheral blood progenitors. Blood. 1990 Jul 15;76(2):330–335. [PubMed] [Google Scholar]
  17. Takaue Y., Watanabe T., Abe T., Okamoto Y., Saito S., Shimizu T., Sato J., Hirao A., Suzue T., Koyama T. Experience with peripheral blood stem cell collection for autografts in children with active cancer. Bone Marrow Transplant. 1992 Sep;10(3):241–248. [PubMed] [Google Scholar]
  18. Tarella C., Ferrero D., Bregni M., Siena S., Gallo E., Pileri A., Gianni A. M. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer. 1991;27(1):22–27. doi: 10.1016/0277-5379(91)90052-f. [DOI] [PubMed] [Google Scholar]
  19. To L. B., Shepperd K. M., Haylock D. N., Dyson P. G., Charles P., Thorp D. L., Dale B. M., Dart G. W., Roberts M. M., Sage R. E. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol. 1990 Jun;18(5):442–447. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES